ArticleOrthopaedic surgery2026
Second-Knee C-Reactive Protein After 1-Week Staged Bilateral Total Knee Arthroplasty.
Article in Orthopaedic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOne-week staged bilateral total knee arthroplasty (TKA) operates the second knee before the systemic response to the first has resolved. Whether a higher second-knee C-reactive protein (CRP) reflects expected carryover or a distinct second-surgery response is unknown. Using each patient as their own control, we assessed how far this burden reflects carryover.
methodsWe retrospectively analyzed 216 patients who underwent 1-week staged bilateral TKA between January 2020 and April 2026 (primary cohort: 210 staged within 9 days). Primary endpoints were the absolute CRP on Postoperative Days 2 and 5, with the Days 2-5 area under the curve as a complementary summary. Exploratory analyses examined the per-surgery CRP increment from each operation's own floor, peak reproducibility, and operative-magnitude adjustment. Paired comparisons used the Wilcoxon signed-rank test.
resultsThe second knee carried a higher absolute CRP burden than the first: median paired differences +1.44 mg/dL at Day 2, +0.70 at Day 5, and +3.74 mg · day/dL for the Days 2-5 area under the curve, all significant after Holm correction and robust to multiple imputation of missing values. From each operation's own floor, the second-knee increment was smaller, but the Day-5 proxy floor exceeded the directly measured pre-second-operation value by a median 2.58 mg/dL, underestimating that increment by the same amount. In the 14 patients with a measured floor and a complete increment pair, the increment difference was -0.55 mg/dL and did not reach significance (p = 0.15); the measured floor was itself of similar magnitude to the Day-2 between-knee difference. Peak CRP showed moderate within-patient agreement (intraclass correlation 0.65).
conclusionsIn 1-week staged bilateral TKA without tranexamic acid or routine corticosteroid, the second knee runs a higher absolute CRP course, consistent with substantial carryover from the first operation; the data cannot exclude an additional per-surgery response or fix its share. Two periprosthetic joint infections occurred, one during the index admission and one at 48 months, and CRP was not tested against infection outcomes, so these data support no diagnostic threshold. A modestly higher second-knee CRP may reflect the expected acute-phase course but must not override clinical suspicion; prospective validation is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.